<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01095185</url>
  </required_header>
  <id_info>
    <org_study_id>BLEPS</org_study_id>
    <secondary_id>2009-016500-24</secondary_id>
    <nct_id>NCT01095185</nct_id>
  </id_info>
  <brief_title>Efficacy of Statin Association With Standard Treatment in Prevention of Recurrent Hemorrhage in Patient With Cirrhosis and Variceal Bleeding</brief_title>
  <official_title>A Randomized, Multicenter,Double Blind,Controlled With Placebo Trial About Efficacy of Statin Association With Standard Treatment in Prevention of Recurrent Hemorrhage in Patient With Liver Cirrhosis and Variceal Bleeding</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Juan A. Arnaiz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Clinic of Barcelona</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, double blind controlled trial in which patients with esophagic
      variceal bleeding treated with standard therapy (endoscopic variceal ligation(EVL) +
      B-blockers), will be randomized to receive statins or placebo. They will be followed up
      during 12 months to determinate whether statins are effective in prevention of variceal
      bleeding recurrence and evaluate patient survival.

      Randomization will be stratified according to the degree of hepatic insufficiency, assessed
      by the Child-Pugh classifications (A,B or C).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A mayor cause of cirrhosis-related morbility and mortality is the development of variceal
      hemorrhage, a direct consequence of portal hypertension. In addition, survivors of an episode
      of active bleeding have a 70 % risk of recurrent hemorrhage within two years of the bleeding
      episode and the highest risk it is situated in the first six weeks after the hemorrhage
      episode.

      The recommended treatment in AASLD guidelines is the combination of non selective
      Betablockers with endoscopic treatment with EVL, with high recurrence (30% in 2 years).

      The hypothesis of this study is that statins are candidates for improving portal hypertension
      treatment in patients with cirrhosis, improving vascular function as well as preventing
      venous thrombotic events.

      Patients with liver cirrhosis and variceal bleeding with standard treatment will be
      stratified and after randomized to undergo either statins (20 mg for 15 days, and after 40
      mg/day) or placebo. They will be followed up for 12 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrence of variceal bleeding and patient survival</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bleeding severity in both arms.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Appearance or progression of Portal Hypertension complications</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Appearance or progression of Portal Vein Thrombosis</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for alternative treatments (transjugular intrahepatic portosystemic shunt [TIPS], surgery)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events of statin treatment</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Cirrhosis</condition>
  <condition>Hypertension, Portal</condition>
  <condition>Bleeding Esophageal Varices</condition>
  <condition>Portal Vein Thrombosis</condition>
  <arm_group>
    <arm_group_label>Standard therapy + Simvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard therapy: Endoscopic variceal ligation (EVL)+ B Blockers (Propanolol titrated until achieve maximum tolerated dose)
Simvastatin (20 mg for 15 days and after 40 mg/day until the end of the study)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard therapy + placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Standard therapy: Endoscopic variceal ligation (EVL)+ B Blockers (Propanolol titrated maximum tolerated dose).
Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin</intervention_name>
    <description>Simvastatin 20 mg for 15 days, then 40 mg until the end of the study.</description>
    <arm_group_label>Standard therapy + Simvastatin</arm_group_label>
    <other_name>Simvastatina</other_name>
    <other_name>Simvastatina Ratiopharm</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Simvastatin placebo</description>
    <arm_group_label>Standard therapy + placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients between 18 and 80 years old.

          -  Clinical criteria and/or analytical, ultrasound and/or liver biopsy consistent with
             the diagnosis of liver cirrhosis.

          -  Hematemesis or melenas within 7 days prior to study inclusion.

          -  Variceal bleeding. Endoscopic diagnosis:

               -  Active variceal bleeding.

               -  Clot or platelet cluster or,

               -  Esophageal varices associated to red blood in esophagogastric lumen in the
                  absence of other sources of bleeding.

          -  Patients with standard treatment for prevention of recurrence of variceal bleeding
             (EVL+B Blockers,Propanolol).

          -  Women of childbearing age should have a urine pregnancy test negative for 7 days
             before commencement of treatment and postmenopausal women must have amenorrhea for at
             least 12 months to be considered not fertile. Potential childbearing women and men
             must commit to use adequate contraception prior to joining the study and during it.

          -  Written informed consent to participate in the study.

        Exclusion Criteria:

          -  Pregnancy or lactation

          -  Presence multiple hepatocellular carcinoma or only diameter&gt; 5 cm.

          -  Renal failure ( Creatinine &gt; 2 mg/dl)

          -  Advanced liver disfunction (Child Pugh &gt; 13 points)

          -  Contraindication for statins.

          -  Patients HIV treated with antiretroviral therapy.

          -  Pre-treatment with portosystemic shunt ( surgical or percutaneous).

          -  Bleeding due to gastric varices.

          -  Patients with total portal vein thrombosis or portal cavernomatosis.

          -  Patients previously treated with endoscopic variceal ligation and B- Blockers (before
             index episode).

          -  Patients previously treated with statins ( one month before the study).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jaume Bosch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clínic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Complejo Universitario Central de Asturias</name>
      <address>
        <city>Oviedo</city>
        <state>Asturias</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Bellvitge</name>
      <address>
        <city>L´Hospitalet del LLobregat</city>
        <state>Barcelona</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Corporació Sanitària Parc Tauli</name>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Arnau de Vilanova</name>
      <address>
        <city>LLeida</city>
        <state>Catalunya</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Pontevedra</name>
      <address>
        <city>Pontevedra</city>
        <state>Galicia</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Puerta del Hierro</name>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Alicante</name>
      <address>
        <city>Alicante</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic</name>
      <address>
        <city>Barcelona</city>
        <zip>08005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital German Trias i Pujol</name>
      <address>
        <city>Barcelona</city>
        <zip>089016</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario del Mar</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Gregorio Marañon</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Canarias</name>
      <address>
        <city>Tenerife</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 29, 2010</study_first_submitted>
  <study_first_submitted_qc>March 29, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2010</study_first_posted>
  <last_update_submitted>March 18, 2015</last_update_submitted>
  <last_update_submitted_qc>March 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Clinic of Barcelona</investigator_affiliation>
    <investigator_full_name>Juan A. Arnaiz</investigator_full_name>
    <investigator_title>Clinical Research Manager</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
    <mesh_term>Esophageal and Gastric Varices</mesh_term>
    <mesh_term>Hypertension, Portal</mesh_term>
    <mesh_term>Gastrointestinal Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

